Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)

Tipranks - Tue Feb 10, 4:02AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSXResearch Report) and Viatris (VTRSResearch Report) with bullish sentiments.

Valentine's Day Sale - 70% Off

Boston Scientific (BSX)

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific yesterday and set a price target of $105.00. The company’s shares closed last Friday at $76.27.

According to TipRanks.com, Steed is a 4-star analyst with an average return of 4.9% and a 56.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $108.14, representing a 40.0% upside. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.

See today’s best-performing stocks on TipRanks >>

Viatris (VTRS)

According to TipRanks.com, Verma is a 4-star analyst with an average return of 11.9% and a 56.0% success rate. Verma covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Jazz Pharmaceuticals, and Corcept Therapeutics. ;'>

Viatris has an analyst consensus of Moderate Buy, with a price target consensus of $13.60.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.